Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

2.9K

Opioid-induced endocrinopathy in cancer patients: an underestimated clinical problem

Tomasz Buss1, Wojciech Leppert

  • 1Department of Palliative Medicine, Medical University of Gdansk, Gdansk, Poland.

Advances in Therapy
|February 6, 2014
PubMed

Insights

Opioids impact the endocrine system, particularly in cancer patients and survivors. Further research is needed to understand and manage opioid-induced endocrine disorders, improving quality of life.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Opioid impact on the endocrine system is well-documented, primarily in non-malignant pain.
  • Research on opioid effects in cancer patients' endocrine systems is limited.
  • Growing population of cancer survivors on long-term opioid therapy necessitates understanding endocrine consequences.

Purpose of the Study:

  • To review existing research on opioid effects on the endocrine system in cancer patients.
  • To highlight clinical consequences of opioid use in this population.
  • To emphasize the need for further investigation into opioid-induced endocrine disorders.

Main Methods:

  • Literature review of studies on opioid therapy and endocrine function in cancer patients.
  • Analysis of clinical implications and consequences.
  • Synthesis of current knowledge and identification of research gaps.

Main Results:

  • Opioid use can cause or exacerbate endocrine disorders.
  • These effects may be more clinically relevant for cancer survivors in remission than for those in active treatment.
  • Awareness of endocrine symptoms associated with opioid therapy is crucial for clinicians.

Conclusions:

  • Opioid analgesics can significantly affect the endocrine system in cancer patients.
  • Further research is essential to address opioid-induced endocrine issues.
  • Managing these endocrine effects is vital for enhancing the quality of life for cancer patients on long-term opioid therapy.

More Related Videos

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.4K

Related Concept Videos

Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.7K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
24
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.2K
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
36